1. |
Shields JA, Shields CL, Honavar SG, et al. Classification and management of Coats disease: the 2000 Proctor Lecture[J]. Br J Opthalmol, 2001, 131(5): 572-583. DOI: 10.1016/s0002-9394(01)00896-0.
|
2. |
Daruich AL, Moulin AP, Tran HV, et al. Subfoveal nodule in Coat's disease: toward an updated classification predicting visual prognosis[J]. Retina, 2017, 37(8): 1591-1598. DOI: 10.1097/IAE.0000000000001399.
|
3. |
Morris B, Foot B, Mulvihill A. A population-based study of Coats disease in the United Kingdom Ⅰ: epidemiology and clinical features at diagnosis[J]. Eye (Lond), 2010, 24(12): 1797-1801. DOI: 10.1038/eye.2010.126.
|
4. |
Shapiro MJ, Chow CC, Karth PA, et al. Effects of green diode laser in the treatment of pediatric Coats disease[J]. Am J Ophthalmol, 2011, 151(4): 725-731. DOI: 10.1016/j.ajo.2010.10.024.
|
5. |
阮露, 黄欣, 江睿, 等. 间接检眼镜下激光光凝治疗青少年型Coats病[J]. 中华眼底病杂志, 2014, 30(1): 42-45. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.011.Ruan L, Huang X, Jiang R, et al. Juvenile Coats disease successfully managed green diode laser using indirect ophthalmoscope[J]. Chin J Ocul Fundus Dis, 2014, 30(1): 42-45. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.011.
|
6. |
Sun Y, Jain A, Moshfeghi DM. Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium[J]. Graefe's Arch Clin Exp Ophthalmol, 2007, 245(9): 1387-1388. DOI: 10.1007/s00417-007-0559-8.
|
7. |
He YG, Wang H, Zhao B, et al. Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab[J]. Graefe's Arch Clin Exp Ophthalmol, 2010, 248(10): 1519-1521. DOI: 10.1007/s00417-010-1366-1.
|
8. |
Kase S, Rao NA, Yoshikawa H, et al. Expression of vascular endothelial growth factor in eyes with Coats' disease[J]. Invest Ophthalmol Vis Sci, 2013, 54(1): 57-62. DOI: 10.1167/iovs.12-10613.
|
9. |
Kodama A, Sugioka K, Kusaka S, et al. Combined treatment for Coats disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases[J/OL]. BMC Ophthalmol, 2014, 14: 36[2014-03-25]. https://pubmed.ncbi.nlm.nih.gov/24666524/. DOI: 10.1186/1471-2415-14-36.
|
10. |
Zhang L, Ke Y, Wang W, et al. The efficacy of conbercept or ranibizumab intravitreal injection combined with lasertherapy for Coats disease[J]. Graefe's Arch Clin Exp Ophthalmol, 2018, 256(7): 1339-1346. DOI: 10.1007/s00417-018-3949-1.
|
11. |
Habib AM. Experience with intravitreal ranibizumab as an adjunct to ablation therapy in eyes with exudative Coats' disease[J]. Clin Ophthalmol, 2021, 15: 367-373. DOI: 10.2147/OPTH.S293030.
|
12. |
中华医学会眼科学分会眼底病学组. 我国视网膜病玻璃体腔注药术质量控制标准[J]. 中华眼科杂志, 2015, 51(12): 892-895. DOI: 10.3760/cma.j.issn.0412-4081.2015.12.005.Chinese Medical Association Ophthalmology Group. Quality control standard of vitreous injection for retinopathy in China[J]. Chin J Ophthalmol, 2015, 51(12): 892-895. DOI: 10.3760/cma.j.issn.0412-4081.2015.12.005.
|
13. |
何晶晶, 孙祖华, 刘晓玲. 局部视网膜激光光凝治疗Coats病的疗效观察[J]. 中华眼底病杂志, 2021, 37(8): 605-609. DOI: 10.3760/cma.j.cn511434-20201010-00487.He JJ, Sun ZH, Liu XL. Efficacy of focal photocoagulation on Coats disease[J]. Chin J Ocul Fundus Dis, 2021, 37(8): 605-609. DOI: 10.3760/cma.j.cn511434-20201010-00487.
|
14. |
安建斌, 马景学, 刘丽娅, 等. Coats病的分期与激光治疗[J]. 中国实用眼科杂志, 2008, 26(10): 1126-1128. DOI: 10.3760/cma.j.issn.1006-4443.2008.10.029.An JB, Ma JX, Liu LY, et al. Classification and laser treatment of Coats disease[J]. Chin Pract Opthalmol, 2008, 26(10): 1126-1128. DOI: 10.3760/cma.j.issn.1006-4443.2008.10.029.
|
15. |
李瑞峰. 眼科激光治疗学概要[M]. 北京: 人民卫生出版社, 1998: 178.Li RF. The profile of ophthalmology laser therapy[M]. Beijing: People's Medical Publishing House, 1998: 178.
|
16. |
Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema[J]. Retina, 2006, 26(9): 999-1005. DOI: 10.1097/01.iae.0000247165.38655.bf.
|
17. |
Li S, Deng G, Liu J, et al. The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat's disease[J]. BMC Ophthalmol, 2017, 17(1): 76. DOI: 10.1186/s12886-017-0469-4.
|
18. |
Jiang L, Qin B, Luo XL, et al. Three-year follow-up of Coats disease treated with conbercept and 532-nm laser photocoagulation[J]. World J Clin Cases, 2020, 8(24): 6243-6251. DOI: 10.12998/wjcc.v8.i24.6243.
|
19. |
Jun JH, Kim YC, Kim KS. Resolution of severe macular edema in adult Coats’ disease with intravitreal triamcinolone and bevacizumab injection[J]. Korean J Ophthalmol, 2008, 22(3): 190-193. DOI: 10.3341/kjo.2008.22.3.190.
|
20. |
Sigler EJ, Randolph JC, Calzada JI, et al. Current management of Coats disease[J]. Surv Ophthalmol, 2014, 59(1): 30-46. DOI: 10.1016/j.survophthal.2013.03.007.
|
21. |
Kaul S, Uparkar M, Mody K, et al. Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats disease in children[J]. Indian J Ophthalmol, 2010, 58(1): 76-78. DOI: 10.4103/0301-4738.58480.
|
22. |
Wells JR, Hubbard GB 3rd. The effect of intravitreal bevacizumab in the treatment of Coats disease in children[J]. Retina, 2011, 31(2): 427-428. DOI: 10.1097/IAE.0b013e318203c01e.
|
23. |
Galliard MC, Mataftsi A, Balmer A, et al. Ranibizumab in the management of advanced coats disease stages 3B and 4[J]. Retina, 2014, 34(11): 2275-2281. DOI: 10.1097/iae.0000000000000248.
|
24. |
Yang Q, Wei W, Shi X, et al. Successful use of intravitreal ranibizumab injection and combined treatment in the management of Coats' disease[J]. Acta Ophthalmol, 2016, 94(4): 401-406. DOI: 10.1111/aos.13067.
|
25. |
Ramasubramanian A, Shields CL. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction[J]. Br J Ophthalmol, 2012, 96(3): 356-359. DOI: 10.1136/bjophthalmol-2011-300141.
|
26. |
Bhat V, D'Souza P, Shah PK, et al. Risk of tractional retinal detachment following intravitreal bevacizumab along with subretinal fluid drainage and cryotherapy for stage 3B Coats' disease[J]. Middle East Afr J Ophthalmol, 2016, 23(2): 208-211. DOI: 10.4103/0974-9233.175895.
|
27. |
Kusaka S. Surgical management of Coats disease[J]. Asia Pac J Ophthalmol (Phila), 2018, 7(3): 156-159. DOI: 10.22608/APO.201867.
|